Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00994123
Recruitment Status : Completed
First Posted : October 14, 2009
Results First Posted : August 22, 2016
Last Update Posted : August 22, 2016
Information provided by (Responsible Party):
Merrimack Pharmaceuticals

Brief Summary:
A Phase 1-2 study of MM-121 in combination with standard therapy for non-small cell lung cancer (NSCLC).

Condition or disease Intervention/treatment Phase
Carcinoma, Non-Small-Cell Lung Drug: MM-121 Drug: Erlotinib Phase 1 Phase 2

Detailed Description:

Phase 1: Patients with Non-Small Cell Lung Cancer (NSCLC) may be enrolled to evaluate the safety, tolerability and recommended Phase 2 dose of MM-121 in combination with standard therapy.

Phase 2: Patients with Non-Small Cell Lung Cancer (NSCLC) may be enrolled to estimate the progression-free survival of the MM-121 + standard therapy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 162 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1-2 Trial of MM-121 in Combination With Erlotinib in Three Groups of Patients With Non-Small Cell Lung Cancer
Study Start Date : February 2010
Actual Primary Completion Date : November 2014
Actual Study Completion Date : June 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

Arm Intervention/treatment
Experimental: Phase 1: Dose-Escalation
Escalating doses of MM-121 (QOW IV) and erlotinib (daily PO)
Drug: MM-121
MM-121 (SAR256212) = intravenous solution
Other Name: SAR256212

Drug: Erlotinib
erlotinib = daily oral tablet
Other Name: Tarceva

Active Comparator: Phase 2: Control
Erlotinib (daily)
Drug: Erlotinib
erlotinib = daily oral tablet
Other Name: Tarceva

Experimental: Phase 2: Treatment
MM-121 (QOW IV) and erlotinib (daily PO)
Drug: MM-121
MM-121 (SAR256212) = intravenous solution
Other Name: SAR256212

Drug: Erlotinib
erlotinib = daily oral tablet
Other Name: Tarceva

Primary Outcome Measures :
  1. Phase 1: To Determine the Recommended Phase 2 Dose of the MM-121 + Erlotinib Combination Based Upon Either the Maximum Tolerated Dose (MTD) or the Maximum Feasible Dose of the Combination in Patients With NSCLC. [ Time Frame: From date of first dose to 30 days after termination, the longest 175 weeks ]
    To establish the safety of escalating doses of MM-121 in combination with erlotinib in order to determine the recommended phase 2 dose of the combination for the second part of the study. Dose-escalation conducted using standard 3+3 model to determine maximum tolerated dose. Reports of Dose-Limiting Toxicities (DLTs) were assessed to determine the MTD.

  2. Phase 1: Determine the Maximum Tolerated Dose Dependent on Reports of Dose-limiting Toxicities [ Time Frame: From date of first dose to 30 days after termination, the longest 175 weeks ]

    Using a 3+3 dose escalation model, the maximum tolerated dose was determined by assessing dose-limiting toxicities in each cohort. If 3 patients were treated and passed the observation window, escalation to the next cohort was initiated. If a DLT was reported, 3-4 additional patients were enrolled and observed. If a DLT was observed in the expanded cohort, this dose was considered to be the maximum tolerated dose. The maximum tolerated dose was defined at the cohort in which two dose-limiting toxicities were observed, or as the highest target dose tested in the absence of DLTs.

    The determined MTD was used as the recommended Phase 2 dose.

  3. Phase 2: Progression-free Survival of the MM-121 + Erlotinib Combination [ Time Frame: Time from first dose to date of progression, with a median of 8.1 weeks ]
    This was a time-to-event measure using Progression-Free Survival (PFS) comparing MM-121 + erlotinib vs.erlotinib alone. Progression of disease is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions". Progression free survival was defined as the number of weeks from the date of randomization to the date of death or progression. If neither death nor progression was observed during the study, PFS data was censored at the last non-progressive disease valid tumor assessment unless the patient was discontinued due to symptomatic deterioration. If this occurred, the patient was counted as having progressive disease (PD).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with locally advanced or metastatic non-small cell lung cancer.
  • Patients must be >/= 18 years of age.
  • Patients must have adequate Performance Status (PS) as measured by ECOG and adequate end organ function.

Exclusion Criteria:

  • Patients with a recent history (within 5 years) of another malignancy.
  • Patients who are pregnant or nursing.
  • Patients with clinically significant heart failure.
  • Patients with clinically significant eye or gastrointestinal abnormalities.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00994123

Layout table for location information
United States, Alabama
Birmingham, Alabama, United States, 35294
United States, Arizona
Tucson, Arizona, United States, 85715
United States, California
Loma Linda, California, United States, 92354
Sacramento, California, United States, 95817
San Francisco, California, United States, 94115
United States, Colorado
Aurora, Colorado, United States, 80045
United States, Florida
Tampa, Florida, United States, 33612
United States, Georgia
Atlanta, Georgia, United States, 30322
United States, Indiana
Lafayette, Indiana, United States, 47905
United States, Massachusetts
Boston, Massachusetts, United States, 02114
United States, Missouri
St. Louis, Missouri, United States, 63110
United States, New York
Buffalo, New York, United States, 14263
New York, New York, United States, 10065
United States, Ohio
Cincinnati, Ohio, United States, 45267
United States, Oregon
Portland, Oregon, United States, 97239
United States, Pennsylvania
Pittsburgh, Pennsylvania, United States, 15232
United States, South Carolina
Charleston, South Carolina, United States, 29425
United States, Tennessee
Nashville, Tennessee, United States, 37232
United States, Texas
Dallas, Texas, United States, 75390
Canada, Alberta
Edmonton, Alberta, Canada
Canada, Ontario
Toronto, Ontario, Canada, M5G2M9
Canada, Quebec
Montreal, Quebec, Canada
Heidelberg, Mannheim, Germany, 68167
Bad Berka, Germany, 99437
Frankfurt, Germany, 60488
Heidelberg, Germany, 69126
Lungenklinik, Germany
Ulm, Germany, 89081
Korea, Republic of
Seoul, Gangnam-gu, Korea, Republic of, 135-710
Seoul, Seodaemun-gu, Korea, Republic of, 120-752
Barcelona, Spain, 08035
Madrid, Spain
Malaga, Spain, 29010
Guishan, Taoyuan County, Taiwan, 33305
Taichung, Taiwan, 40705
Taichung, Taiwan
Tainan City, Taiwan, 70146
Taipei, Taiwan, 100
Sponsors and Collaborators
Merrimack Pharmaceuticals
Layout table for investigator information
Study Director: Victor Moyo, MD Merrimack Pharmaceuticals
Layout table for additonal information
Responsible Party: Merrimack Pharmaceuticals Identifier: NCT00994123    
Other Study ID Numbers: MM-121-01-101
First Posted: October 14, 2009    Key Record Dates
Results First Posted: August 22, 2016
Last Update Posted: August 22, 2016
Last Verified: July 2016
Keywords provided by Merrimack Pharmaceuticals:
Non-Small Cell Lung Cancer
Advanced Non-Small Cell Lung Cancer
Metastatic Non-Small Cell Lung Cancer
Lung Cancer
Epidermal Growth Factor Receptor
anti-ErbB3 human monoclonal antibody
ErbB3 antagonist
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Erlotinib Hydrochloride
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action